Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DQ2B | ISIN: US8051111016 | Ticker-Symbol: YB4P
Frankfurt
24.04.25
14:01 Uhr
2,820 Euro
-0,040
-1,40 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
SAVARA INC Chart 1 Jahr
5-Tage-Chart
SAVARA INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,8402,88018:27
2,8402,88018:21

Aktuelle News zur SAVARA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiJMP maintains $10 target on Savara stock post-BLA submission1
07.04.Savara to present aPAP treatment study at medical congresses1
07.04.Savara Inc.: Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences348Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase...
► Artikel lesen
SAVARA Aktie jetzt für 0€ handeln
31.03.Savara: Loan & Security Agreement Signed For Up To $200 Million With Hercules Capital6
28.03.Savara stock holds Buy rating, $6 target from H.C. Wainwright1
27.03.Savara Inc Q4 Loss Increases, Misses Estimates1
27.03.Savara Inc - 10-K, Annual Report1
27.03.Savara GAAP EPS of -$0.131
27.03.JMP maintains $9 target on Savara stock, sees FDA nod1
26.03.Savara secures $200M loan to support respiratory drug launch6
26.03.Savara Inc - 8-K, Current Report3
26.03.Savara submits FDA application for aPAP therapy MOLBREEVI3
06.03.Savara Launches New Dried Blood Spot Test For APAP Diagnosis2
23.01.Savara Inc - 8-K, Current Report-
13.01.Savara Inc - 8-K, Current Report2
13.11.24Savara downgraded at Evercore on manufacturing concerns for lung disease candidate3
12.11.24Savara Reports Third Quarter 2024 Financial Results and Provides Business Update 194LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third...
► Artikel lesen
15.08.24Savara Inc.: Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024433Company-Sponsored Industry Symposium To Be Held at the ERS Congress Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases,...
► Artikel lesen
12.08.24Savara Reports Second Quarter 2024 Financial Results and Provides Business Update146LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second...
► Artikel lesen
26.06.24Pre-market Movers: Syntec Optics, Anew Medical, Rivian Automotive, Volcon, Inc., Savara627MEMPHIS (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.25 A.M. ET).In the Green Syntec Optics Holdings, Inc. (OPTX) is up over...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1